How effective is PGT-M for thalassaemia carrier?

Thalassaemia is inherited through gene changes affecting haemoglobin. A carrier may have no major symptoms but can pass a relevant change to a child. PGT-M uses embryos created through IVF: cells are tested for the known familial change, and the fertility team discusses which embryos may be suitable for transfer. It does not repair an embryo, test every possible health condition, or guarantee pregnancy or a healthy birth. A genetic consultation is needed to confirm the exact change and design a reliable test. The result may be less straightforward when both partners carry different changes or when the family diagnosis is unclear.

Ask for genetic counselling before starting treatment. Bring any haemoglobin or genetic reports from relatives, and arrange testing for both partners when advised. The IVF team can explain ovarian stimulation, egg collection, embryo testing, and the possibility that no embryo is suitable for transfer. Discuss whether prenatal testing is recommended after pregnancy begins, because embryo testing has limits and results may need confirmation. Consider emotional support as well as the medical plan; decisions can feel difficult when testing, treatment, and family risk overlap.

Contact the fertility or genetics team promptly if you receive an uncertain test result, develop severe pain or heavy bleeding during fertility treatment, or feel unwell after egg collection. Seek urgent medical care for fainting, breathing difficulty, severe abdominal swelling, or heavy bleeding. If you are already pregnant, tell your maternity team about the carrier result and any PGT-M report so they can arrange appropriate counselling and pregnancy testing.

What exact thalassaemia gene change is present in our family? How will the laboratory check that change in embryos? What happens if few or no embryos reach testing? Which pregnancy test can confirm the result, and when should it be offered?